RecruitingAsthma
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Single center, randomized, placebo- controlled study to assess change in mucociliary clearance of moderate to severe asthma patients after treatment with dupilumab or placebo.
Sponsor: Sally E. Wenzel MD
You may qualify if…
- ✓ Moderate - Severe Th2 (Type 2) High asthma, as defined by Forced Expiratory Volume in one second (FEV1) \<90% predicted, on medium to high dose inhaled corticosteroids (ICS) with or without a second controller
- ✓ Age \> 18
- ✓ Inhaled steroid doses of 500micrograms (mcg) per day or more (Fluticasone equivalent)
- ✓ Reversibility \>/= 12% at screening or within the past 2 years, or a positive methacholine challenge test within the past 2 years, or a positive methacholine challenge during screening
- ✓ FEV1/Forced Vital Capacity (FVC)\<75%
- ✓ Blood Eosinophils (EOS) \>300 cells per mm3
- ✓ Exhaled Nitric Oxide (FeNO) \>25 parts per billion (ppb)
- ✓ Asthma Control Test (ACT) score \<20
You may not qualify if…
- ✕ Pregnant, nursing, or unwilling to test for pregnancy
- ✕ Current smoker or \>10 pack year smoking history
- ✕ Body Mass Index (BMI)\>37
- ✕ Respiratory infection in the last 30 days
- ✕ Use of antibiotics or oral prednisone in the last 30 days
- ✕ Current or previous use of dupilumab
- ✕ Current or recent use of anti-IL-5 therapies
- ✕ Any other criteria that place the subject at unnecessary risk
Where it's recruiting
Pennsylvania
Pittsburgh
Source: ClinicalTrials.gov · NCT04743791 · last updated 2025-11-10